1. BDX will host a financial webcast on May 1, 2025. 2. The webcast will cover Q2 2025 financial results and strategy updates. 3. Pre-call materials will summarize key financial information for investors. 4. BDX aims to enhance healthcare quality and efficiency globally. 5. The company has over 70,000 employees focused on healthcare innovations.
Upbeat financial forecasts and strategic insights can drive positive investor sentiment; previous earnings calls have often led to upward stock movements.
The announcement of earnings and strategic updates is critical for investor confidence, directly impacting BDX's stock valuation.
Market reactions to earnings announcements typically manifest quickly, influencing stock price in the days following the release.
/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, May 1, 2025 to discuss the Company's financial results for its second quarter of fiscal year 2025, which ended on March 31, 2025, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors, and a replay will be made available shortly after the call at the same website. Prior to the call, the Company will issue a news release and related presentation materials that will include summary financial information for the quarter. The news release and related presentation materials will be made available at www.bd.com/investors.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Troy Kirkpatrick
VP, Public Relations
858.617.2361
troy.kirkpatrick@bd.com
Adam Reiffe
Sr. Director, Investor Relations
201.847.6927
adam.reiffe@bd.com
SOURCE BD (Becton, Dickinson and Company)